-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Title:
Journal: , ,
China and
Published: 2019/6/16
DOI:10.1155/2019/3808432
Abstract:
abnormal expression of Eya2 has been observed in multiple cancer types. However, the clinical significance and biological effects of Eya2 in human prostate cancer remain unclear. In this study, we found that elevated Eya2 protein levels were associated with late TNM, T-phase, and elevated Gleason scores. Data from the Cancer Genome Map (TCGA) prostate queue consistently showed that Eya2 mRNA was positively associated with higher Gerason scores, higher T-stages, and positive lymph node metastasis in prostate cancer. In addition, data from the Oncomine database showed elevated levels of EYA2 mRNA expression in prostate cancer tissue compared to normal tissues. The Eya2 protein is also expressed higher in prostate cancer cell line than normal RWPE-1 cell line. We chose LNCaP and PC-3 cell line for granulation overextending and shRNA knock-out. Experiments on CCK-8, colony formation and substrate gel invasion show that Eya2 overexpression promotes proliferation, colony number and invasion, while Eya2 shRNA inhibits proliferation rate, colony formation and invasion. CCK-8 and Annexin V tests showed that Eya2 reduced the sensitivity of dositas and dosital-induced apoptosis, while Eya2 shRNA showed the opposite effect. Eya2 overexploitation also reduced the cracking of caspase3 and PARP, while Eya2 exhaustion increased the cracking of caspase3 and PARP. Notably, the JC-1 stain shows that Eya2 has raised the mitochondrial membrane level. We further found that the overexploitation of Eya2 increased Bcl-2, substitin metal protease 7 (MMP7) and AKT phosphate. Therefore, data from the TCGA prostate queue show that EYA2 mRNA is positively related to the expression of Bcl-2 and MMP7. The inhibition of AKT weakened the eya2-induced Bcl-2 increase. Overall, our data show that Eya2 is elevated in prostate cancer. EYA2 promotes cell proliferation and invasion, as well as cancer development, by regulating polyene yew alcohol sensitivity and mitochondrial membrane potentials (possibly via AKT/Bcl-2 axis).
。 (Source: Science.com)
